ASIAN JOURNAL OF CLINICAL PERINATOLOGY AND PEDIATRIC BIOLOGY

VOLUME 1, 2026

Inflammatory Cytokine Profiles as Predictors of Neonatal Respiratory Morbidity

*Sutha Devaraj[1] and Rashid MA[2]

[1]School of Medicine, Perdana University, Damansara Heights, Kuala Lumpur, Malaysia
[2]Faculty of Medicine, AIMST University, Bedong, Kedah, Malaysia

*Correspondence: sutha@perdanauniversity.edu.my

Submitted: 05 Sep 2025, Revised: 25 Oct 2025, Accepted: 15 Jan 2026

https://doi.org/10.64799/ajcppb.V1.I1.5

Abstract

Neonatal respiratory morbidity continues to be an important cause of early-life morbidity, and is traditionally explained by the developing lung's structural and mechanical immaturity. However, the more evidence grows about the role of immune dysregulation during the perinatal period and its critical importance to respiratory adaptation, the more this explanation may need to change. In this study, we focus on the correlation of the severity of respiratory morbidity to inflammatory cytokine levels in neonatal and cord blood. Using multiplex cytokine analysis along with hierarchical clustering, several levels of modeling, and predictive analysis, we were able to characterize distinct inflammatory signatures in morbid neonates and compared them to the absence of morbid conditions at all levels. The association of higher levels of pro-inflammatory cytokines and lower levels of counter-regulatory ones to the need for more oxygen and the lung machine, further respiratory distress, the incidence of bronchopulmonary dysplasia, and the need for longer ventilation is described. The burden of composite inflammation showed to provide more accurate models for a morbid condition's prediction than linear models for the respiratory outcomes. The evidence allows for a prediction of the inflammatory signatures to serve as an important early assessment of the at risk condition pre- and post- birth.

Keywords: neonatal respiratory morbidity; inflammatory cytokines; immune–respiratory crosstalk; cord blood biomarkers; risk stratification

1. Introduction

During the neonatal period, the development of respiratory complications has the potential to cause life-threatening issues, extend hospital stays, and create long-term issues with the lungs, especially in preterm infants or those who are restricted in growth. In the past, the respiratory concerns in neonates were primarily attributed to the immaturity of the lungs and the mechanics of the lungs, involving the lungs and the surfactant deficiency, incomplete alveolar development, and the reduction of compliance in the lungs. These factors have contributed to the understanding of this problem. However, several studies show that this understanding is too simplistic. There is a process of ongoing inflammation in the lungs of neonates that has worsened the problem, and the signaling of the immune system is central to this process, and has the potential to impact how the lungs develop and how injury is sustained [1], [2].

Immediately after birth, the lung experiences its first and most rapid inflammatory transition, from being filled with intrauterine fluids to taking the first breath of air, which, in addition to the aforementioned, will include exposure to oxidative stress, mechanical stretch and microbes. This transition, and the subsequent re-opening of the lung alveoli, requires coordination of several processes, such as epithelial maturation, angiogenic and lymphatic remodeling, and the establishment of immune tolerance. Among these processes, inflammatory signaling is paradoxically both essential for normal lung development, and when dysregulated, leads to damaging inflammatory responses [3]. Uninhibited or excessive inflammation during this narrow developmental window contributes to a cascade of respiratory complications, most notably respiratory distress syndrome (RDS), prolonged oxygen dependency, and later, bronchopulmonary dysplasia (BPD) [4].

One of the earliest predictors of respiratory problems in newborns is antenatal inflammation. The effects of chorioamnionitis, mother's infection, or immune activation of the placenta as inflammatory stimuli encountered in the womb have been correlated with altered developmental pathways of the fetal lung, and respiratory distress after birth [5], [6]. These inflammatory factors, encountered antenatally, prepare the fetal lungs and immune system with structures and functions that are adaptive, or more susceptible, to injury after birth. Both experimental and clinical studies suggest that although certain aspects of lung maturation may be positively influenced by some of the inflammatory mediators present in the womb, the lungs will be more susceptible to inflammation post birth [7].

In the immediate newborn period, this risk is worsened by perinatal inflammation. Forced mechanical breathing, oxygen, and the presence of pathogens may worsen the inflammatory signals present in the immature lungs, especially when there is pre-existing immune activation [8]. Crucially, not all neonates faced with identical mechanical challenges develop the same degree of respiratory problems, which indicates that the inflammatory state at birth and other biological factors differ and affect the risk.

The presence of this heterogeneity highlights the importance of going beyond mechanical factors, and considering integrated biological factors to explain immune-respiratory dynamics [9]. Cytokines have prominent roles at the immune–respiratory interface. As soluble molecules, they govern the recruitment of immune cells, epithelial repair, the induction of vascular permeability, and tissue remodeling. In the maturing lung, the context-dependent effects of cytokines, including interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor–α (TNF-α), and in particular the anti-inflammatory IL-10, may support adaptation or propagate injury [10]. Thus, the outcome of neonatal lung inflammation hinges on the ratio of pro-inflammatory and regulatory cytokines and whether they act in support of repair or in the injury of chronic inflammation.

Cytokines do not act in isolation, and integrate the signals of the immune, pulmonary epithelial, and vascular systems. This network-level function is what makes cytokine profiles appealing as biomarkers; they reflect an integrated, systemic response rather than a single, isolated, pathway response. Composite measures of inflammation have shown to better predict respiratory outcomes than single cytokine measurements [11]. Such profiles reflect the cumulative effects of immune system activation and regulation, and provide a window into the biological state of the newborn.

The temporal aspects of cytokine evaluation play a role in its ability to forecast/determine events. Blood from the umbilical cord and the first few hours of the baby's life offer a rare opportunity for future analysis of the potential inflammatory processes occurring at the moment of the baby's first breath. Levels of cytokines in cord blood are a summation of factors like maternal prenatal care, the immune communication from the placenta, and the immune reaction from the fetus, making them excellent indicators of the inflammatory factors present both during and after pregnancy [12]. In contrast to samples collected after birth, which may be complicated by medical procedures, bacterial infections, or incipient pathological processes, umbilical cord blood demonstrates isotropy and unambiguity in its inflammatory attributes.

Blood drawn from the baby in the first hours of life broadens this opportunity to include the primary immunological reaction to the birth trauma, which may include hypoxia and artificial respiration. The period shortly after birth is defined by considerable immune restructuring and is characterized by the presence of inflammatory factors that can affect the development of the lungs [13]. The cytokine levels during this period can give important indicators about the baby's ability to withstand respiratory challenges and recuperate from injuries to the lungs.

Inflammatory cytokine profiles at birth have ramifications for respiratory outcomes, both immediate and chronic. The occurrence of certain pro-inflammatory cytokines is concerning, as the severity of RDS, extended need for mechanical ventilation, and development of BPD were attributed to their presence. In contrast, some regulatory cytokines appear to mitigate the impact of inflammation as tissue repair is facilitated, thus, granting protection BPD development [14]. A clear link is established between the respiratory pathophysiology and the cytokine

profiles; thus, the profiles should be used reflectively, as catalysts to disease progression, rather than causally as epiphenomenon of disease.

The predictive strength of respiratory disease cytokine signatures is increased as there is evidence of their presence prior to the manifestation of the disease. In a number of cohort studies, episodes of cytokine dysregulation were noted prior to the occurrence of respiratory failure, suggesting that immune dysregulation is likely to be a precursor rather than a result of lung disease [15]. There is reason to accept cytokine signatures as predictive markers of the risk for irreversible damage in the most vulnerable neonates.

Even with a more extensive compilation of proof, cytokine data has frequently been evaluated in a vacuum or confined to individual markers, thus limiting their translational scope. There is a need for a more comprehensive model that captures cytokine networks and systemically integrates respiratory outcomes in order to fully understand their predictive capacity. This is particularly congruent with contemporary conceptualizations of neonatal respiratory morbidity as a systems-level disorder due to the child's interplay with the immune, developmental, and environmental factors [16].

In this context, the current study is centered on the predictive capacity of inflammatory cytokine profiles in neonatal respiratory morbidity, particularly as predictive constituents of immune–respiratory cross-talk. With the analysis of cytokine profiles from cord blood and early neonatal samples, this study endeavors to elucidate the relationship between birth inflammatory burden and respiratory adaptation and the extent of morbidity. The development of cytokine-based predictors of respiratory risk could advance early stratification, improve focused watch, and deepen the insight concerning the immune-driven programming of the lungs and their development.

2. Study Design and Cytokine Profiling Framework

The purpose of this study was to focus on the signaling of inflammatory cytokines as an early integrative factor of respiratory illness in newborns, particularly on how the distinct patterns of immune activation present at birth translate to respiratory illness after birth. Instead of treating the cytokine measurements as an unconnected laboratory value, the analytical structure retained a biological and chronological association of measurements, as well as an association to an outcome throughout the entire data continuum. As a consequence, this design consolidates neonatal sampling, the quantification of cytokines using a high throughput technique, data normalization, and modeling of outcomes into a single analytical process, as shown in Figure 1.



Figure 1. Integrated cytokine profiling and outcome linkage workflow

The inclusion of the neonates was aimed at obtaining a clinically meaningful range of respiratory related outcomes while keeping unrelated systemic pathology confounding to a minimum. Infants were recruited at birth and were placed into groups based on respiratory outcomes, which ranged from no respiratory illness to mild, moderate, or severe illness with associated respiratory distress, and/or the need for step-up respiratory support of varying levels. Gestational age and birth weight were considered as continuous variables, not as dichotomized cut-off values. This approach allowed for modeling in the inflammatory domain that was distinct from the domain of maturation. Because the study design was centered on biological sampling from early life and definitive respiratory outcomes, it created the framework to guarantee that the clinically relevant and temporally appropriate context would be applied to all the cytokine profiles.

The first step in the workflow involved the acquisition of samples. To keep the modification after birth as low as possible, samples of cord blood were taken straight after delivery to capture inflammatory exposure in the antenatal and intrapartum stages. If there was no cord blood, or if there was a technical issue concerning the cord blood, the early neonatal peripheral blood samples taken within hours after birth were used to further the inflammatory exposure into the immediate postnatal period. This approach captures real-world clinical constraints while maintaining biological continuity. All samples were processed as per standardized procedures in order to minimize pre-analytical variability, such as in the systems of anticoagulation, temperature control, and quick separation of plasma.

Post acquisition, samples were analyzed to measure levels of cytokines. In this stage, inflammatory mediators were quantified using either multiplex bead-based immunoassays or enzyme linked immunoassays, depending on the abundance of the cytokine and the required sensitivity of the assay. The selection of cytokines was due to their roles in neonatal immune signaling and lung injury. This spanned the pro inflammatory and the regulatory mediators. Core analytes were IL-6, IL-8, TNF-α, IL-10, and MCP-1. These cytokines capture a couple of elements of the inflammatory process, such as acute inflammatory stimulation, chemotactic signaling, and the control of counter-regulatory immunity. Measuring all these cytokines at once helps recreate immune balance as opposed to single marker interpretation.

The use of multiplexing systems in neonatal research was justified by their ability to measure several analytes from a small biospecimen. In comparison to individual analyte assays, these systems also maintain intra-assay calibration and minimize batch variation. In instances where ELISA methodologies were used, they were limited to those cytokines where there was a need for multiplex result confirmation or sensitivity. All assays were performed as per the instructions of the manufacturer, including the use of internal controls and duplicates to demonstrate reliability.

The data were systematically normalized to address variability between the samples and assays. In Figure 1, this stage of the analysis is depicted as a convergence node, which illustrates the importance of this stage in the analysis. Some cytokine concentrations were log-transformed to increase homogeneity of variance and to reduce negative skew, and adjust for the location of the confirming outliers. The framework applies the same standard of relative concentrations across all cytokines, which reduces the impact of technical artifacts while retaining the underlying biological relationships in relative concentrations.

Procedures for quality control were interwoven with the normalization process. Review was done on flagged samples rather than excluding them automatically. This was done to allow for review if the missing data were due to biological extremes or technical problems. This approach avoids bias against severe clinical cases as missing data are most informative for outcome modeling. The result is a dataset that emphasises data integrity and biological inclusiveness.

After normalization, cytokine data were incorporated into outcome-focused analytical models. The framework allows for continuous and stratified analyses and is a significant advantage as it allows for the exploration of dose-response relationships. Composite inflammatory burden scores were created by summing up the normalized cytokine data. These scores are indicative of the total immune activation state at birth. The composite measures are used for correlation analyses, multivariate stratification, and predictive modeling in subsequent sections.

Let us begin with describing the novelty the integrated framework has to offer the Outcome Modeling that requires depicting the clinical heterogeneity of neonatal respiratory morbidity. The respiratory endpoints shoot oxygen requirement, respiratory support time, and the progression to higher tiers of respiratory support. Modeling these outcomes along the severity continuum is avoiding clinically relevant nuance oversimplifications. As a reminder, the outcomes linked to cytokine data, in the absence of postnatal inflammatory markers collected beyond the disease onset, means predictive associations promote early immune state rather than its downstream effects.

As a software-style laboratory information integrated with Figure 1, we summarize the integrated framework and describe the information analytics pipeline and not the conceptual flowchart. Each component, including sample collection, cytokine measurement, and outcome modeling, is described as a functional module with its specific inputs and outputs. Along with the pipeline presentation, the focus on the analytics layer of the framework emphasizes reproducibility integrated with auditability to analytics traceability. The pipeline, akin to audit and spinal analytics traceability, reflects the best analytics in the biomarker research environment, where analytics provenance and transparency are a necessity.

Alongside the analysis workflow, we present Table 1, which summarizes the characteristics of the neonatal cohort alongside parameters from the cytokine assays. Distributions of Gestational age and birth weight help

situate the inflammatory findings pertaining to the degree of developmental maturity. The categories of Respiratory morbidity appropriately define the clinical range of interest. This ensures that the predictions of the cytokine levels are appropriately tuned to the degree of outcome through the severity of the Respiratory morbidity. The table also explains the cytokines used and the assays that were employed, reiterating the transparency in the process and facilitating the comparison of the findings with the available literature.

Table 1. Neonatal cohort characteristics and cytokine assay overview

Parameter	Value / Description
Neonates enrolled (n)	72
Gestational age (weeks, mean ± SD)	33.8 ± 3.1
Birth weight (g, mean ± SD)	2145 ± 620
Respiratory morbidity distribution (%)	None 30.6 · Mild 27.8 · Moderate 23.6 · Severe 18.0
Sample source	Umbilical cord blood / early neonatal blood
Cytokines quantified	IL-6, IL-8, TNF-α, IL-10, MCP-1
Assay platform	Multiplex bead-based immunoassay (ELISA validation subset)

The interplay of anti-inflammatory and pro-inflammatory cytokines in Table 1 is intentional and it embodies the study focus interest in the immune equilibrium, and not simply the presence of pandemic fuelling inflammation. The presence of IL-6 and TNF-α signalling in the acute and systemic phases of inflammation, IL-8 concerning the recruitment of neutrophils and pulmonary chemotaxis, MCP-1 pertaining to the monocyte focused inflammatory signalling and IL-10 as an important anti-inflammatory control in the respective panels, adds up to the rich description of the immune and the respiratory interplay that is important in the neonatal lung maturation process.

Table 1 combines assay specifics and cohort characterization which facilitates the anchoring of the biological findings to a specific population and measurement approach. This is important for result downstream interpretation and generalizability assessment. Reviewers and readers can assess whether the measured cytokines are likely to be of interest and biologically functional and are not an artifact of the cohort or assay composition and techniques.

An important positive attribute of this study design is the clear distinction it makes between data generation and data interpretation. Data generation for cytokine measurements, and data normalization are done independently of the modeling of outcomes, thus, minimizing the chance of circularity or overfitting. The modeled outcomes are defined using the data and the associations are examined using clear consistent analytical frameworks so that the data speak for themselves without imposing preconceived expectations. This distinction augments the validity of the predictive analyses and further justifies the findings.

3. Results: Neonatal Cytokine Signatures Associated with Respiratory Morbidity

This section describes the core biochemistry linking inflammatory signaling in the early life stage of development to respiratory morbidity in neonates, concentrating on the coordinated patterns of cytokines and how they influence clinically significant outcomes, as opposed to using only a few peripheral markers. Using the different techniques of hierarchical clustering, multivariate projection, and effect-size based summarization, it is shown that the cytokine profile of newborns on the day of delivery contains organized data pertaining to the level of respiratory risk. To avoid reference-less visuals and ambiguity, Figures 2 and 3 and Table 2 are used as anchors for the interpretation of the analysis.

In Figure 2, the heatmap shows the profiles of the inflammatory cytokines obtained from the neonates and the cord blood, utilizing z-score normalization, which emphasizes the relative differences for the various analytes for the different subjects. The cytokine and sample hierarchy shows the comparison of the neonates based on the severity of respiratory morbidity. The infants who did not have any respiratory morbidity are together, and are characterized by low levels of the endothelial pro inflammatory cytokines and they do not have any of the regulatory mediators. On the other hand, the neonates who have a respiratory morbidity which is clinically significant are divided into distinct groups with elevated levels of cytokines such as IL 6 and IL 8 and TNF alpha and a relative decrease of IL 10 which signifies a swing of the immune balance towards the pro inflammatory side.



Figure 2. Heatmap of inflammatory cytokine profiles

In figure 2, we see a good example of a clustering structure. The consistent clustering across a number of cytokines that characterize different functional "arms" of inflammation is quite notable. For instance, the 'systemic inflammatory response' (SIR) components, IL-6, and TNF-α, cluster together with IL-8, which is a prominent player in neutrophil recruitment and pulmonary chemotaxis. Furthermore, MCP-1, an exemplar of

monocyte-mediated inflammatory signaling, reinforces the presence of a pro-inflammatory construct within the constellation of active components that validate the concept of immune response coordination as opposed to singular or isolated pathway activation. The unique position of IL-10 within the cluster alludes to the discordant regulatory feature of the profile, which is associated with more respiratory morbidity; a phenomenon in which counter regulation appears to be insufficient within the neonates that go on to experience more pronounced respiratory deterioration.

There is a more subtle ordering of cytokines in figure 2 with the movement of neonates with mild respiratory morbidity. In the clustering dendrogram, they occupy an intermediate position that connects the cytokine profiles of the unaffected and those of the severely affected infants. Supporting the hypothesis that neonatal respiratory morbidity, with an inflammatory burden, is a continuum rather than a static pathological state, the dendrogram captures a progressive spectrum of the condition. The heatmap captures the concept that with every increasing level of immune activation recorded at birth, there is a corresponding increase in the severity of respiratory outcome.

Though promising, the analysis of cytokine perturbation using hierarchical clustering lacks the requisite quantification of separation and dimensionality, which multivariate projections provide. Figure 3 provides primary component analysis-based multivariate stratification of neonates along the defined cytokine axes. The indicated axes contain the majority of the total variance of the primary components, and the values of the explained variance are provided for ease of understanding. These components are a reflection of combined signal output, with the positive signal output largely attributed to pro-inflammatory components and the negative signal output largely attributed to the regulatory mediators.



Figure 3. Multivariate stratification of neonates based on cytokine profiles

In this low-dimensional hyperspace, the unique positioning of the neonates reveals segregation by the respiratory morbidity classification. The neonates in the no respiratory morbidity category aggregate in the low inflammation region, while the neonates in the severe respiratory morbidity category are positioned in the pro-inflammatory signal high region. The cases in the mild category also cover this span, adding to the hypothesis that the gradients are pro-inflammatory. The clear lack of overlap in signal position of the no respiratory morbidity and severe respiratory morbidity categories signal that the birth cytokine profile is reflective of the respiratory risk stratification at the population level.

The shape of Figure three provides more evidence for a network-based understanding of cytokine signaling. Rather than signaling along a single pathway, morbidity-associated signaling occurs along a multi-dimensional pathway, indicating that several cytokines may work together to increase respiratory risk. This is in line with the current understanding of models of neonatal lung injury, which focus on the interplay of multiple immune factors rather than on single cytokine causation. The multivariate separation, then, corresponds to the clustering shown in figure two by offering empirical proof of the ordering of cytokine profiles, and valuable outcomes in relation to the information they replicate in a low-dimensional manner.

In order to translate these pattern-based observations into analyte-specific associations, table two captures some of the most significant cytokines associated with neonatal respiratory morbidity, along with indications of change, effect size, and adjusted significance. One of the largest positive effect sizes is observed with IL-6, with levels that are elevated associated with the higher morbidity severity, which is in line with IL-6 as an acute phase cytokine and a promoter of systemic inflammation in neonatal lung injury. IL-8 reflects a similar association, which is positive and strong, and is in line with its function of neutrophil recruitment and in the amplification of the inflammatory cascade in the lungs.

Table 2. Key cytokines associated with neonatal respiratory morbidity

Cytokine	Direction of change with increasing morbidity	Effect size (standardized β / $\log_2$ change)	Adjusted significance (FDR)
IL-6	Increased	+0.72	< 0.001
IL-8	Increased	+0.81	< 0.001
TNF-α	Increased	+0.58	0.002
MCP-1	Increased	+0.44	0.006
IL-10	Decreased	−0.46	0.004
IL-1β	Increased	+0.39	0.009

The encapsulated effect size for TNF-α represents one of the driven variables on inflammatory lung tissue damage and lung vasculature injury. MCP-1 reflects a positive association and, in this case, in the presence of tissue damage and inflammation, the function of monocytes may, in collaboration, drive inflammatory tissue damage or may serve a secondary role, with several other processes more actively driving damage. In the case of neonatal respiratory morbidity, the lower IL-10 levels are clinically inversely proportional, and the less severe respiratory outcome the neonate has, the more IL-10 present. This phenomenon correlates with the phenomenon

of regulatory inadequacy, structurally, in some capacity driving the levels of inflammation present.

The significance level on the table suggests the association, after adjustment for multiple comparison tests, still holds. This means it is not exclusively a biostatistical phenomenon, and most of the time, it is related to the phenomenon observed. It is satisfactory that the effect size is similar to the cluster and separated variables in the multivariate analysis in Figures 2 and 3. The cytokines that are separated in the multivariate analysis and serve as primary drivers of the separation of the samples are the same cytokines that serve the greatest effect.

Combining Figures 2 and 3, along with Table 2, allows for a focused interpretation: neonatal respiratory morbidity is linked with a specific inflammatory cytokine profile present at the time of birth. This profile features heightened levels of inflammatory cytokines with little or no regulatory countering, indicating an immune suppression that could increase the likelihood of damage to the vulnerable lung during the early stages of postnatal lung adaptation. The incrementally increasing levels of cytokines with different morbidity levels indicate that inflammatory burden increases with respiratory morbidity severity and is not simply an on–off mechanism.

The results also emphasize the benefits of network or profile-based approaches over single analyte approaches. While individual cytokines such as IL-6 and IL-8 have strong associations with respiratory morbidity, IL-6 and IL-8 lose predictive and explanatory power as single analytes in the larger context of the inflammatory cytokine network as a whole. Figure 3 illustrates that in the presence of multiple dimensions, predictive and separative power can be utilized; this would not have been possible with one single analyte alone and emphasizes the need for a more networked/integrative approach for biomarker research in the neonatal population.

The signatures of the cytokines studied can be explained from the relevant biology through the lens of immune–respiratory crosstalk. Increased levels of the pro-inflammtory cytokines lead to increased vascular permeability, recruitment of leukocytes, and injury to the epithelium. All of these can lead to worsening imbalances of gas exchange and morphology of the lungs in the newborn. The IL-10 reduction indicates insufficient counter-regulatory signals which limits inflammatory resolution and increases the susceptibility of the tissues. So, the patterns of the cytokines show the mechanisms which explain the respiratory distress from the immune dysregulation to the baby in the first place.

The clinical perspective of the coherence of the cytokines and the morbidity suggests a possible first order of discriminatory screening. This part has no prediction; it has an associative and descriptive style, which is why in such a case the empirically defined structure separation in Figure 2 and in Figure 3 provides the basis conceptual space for what is to come for the analysis of outcome. It is critical that the profile of the cytokines is more informative than gestational age and birth weight because it denotes a value which other factors are traditionally considered to be risks.

4. Functional and Predictive Implications of Cytokine Dysregulation

The cytokine signature present in neonatal blood at delivery goes beyond the strictly descriptive and chronological to signal functions related to the early respiratory adjustment and the risk for disease. With composite indices of inflammatory burden derived from individual cytokine measurements, the hypothesis of the immune activation theory can be aligned with inflammatory responses of the respiratory system that are clinically observable. This in part explains the disregulated cytokine signaling and subsequent respiratory function deficiency, and the inflammatory profiles' predictive potential along the continuum of neonatal respiratory morbidity, with particular emphasis on Figures 4 and 5 and Table 3.

Figure 4 depicts the MATLAB-style three-dimensional response surface that represents the correlation of the inflammatory burden and the key respiratory outcomes, which are the three axes of the surface. It is a representation of the composite cytokine load in relation to the oxygen requirement and the volume of the ventilatory support, in order to describe the intensity and the persistence of the respiratory compromise. There is a clearly definable and substantial distance between the regions on either side of the cytokine burden (zero to three milligrams of cytokine burden is silent, and beyond that is all response). With three milligrams of cytokine burden, the respiratory support requirement is at a normal threshold, and beyond that, there is steep, unrelenting oxygen deprivation and longer ventilatory support (more than three inflammatory units). This suggests that there is a zone of tolerable inflammation, which should be clinically confirmed, and beyond that, the neonatal lung's adaptive response is overwhelmed by inflammatory dysregulation, leading to the respiratory morbidity that is clinically important.



Figure 4. Correlation surface linking inflammatory burden to respiratory outcomes

The surface in Figure 4 illustrates the biological reality of immune-respiratory interactions in the developing lung. Pro-inflammatory cytokines (e.g., IL-6, IL-8, and TNF-α) promote vascular permeability, leukocyte infiltration, and injury to lung epithelium, all of which directly impair gas exchange and lung compliance. If these signaling processes are counter balanced by regulatory processes, adaptive repair and resolution may occur. However, the respiratory support requirements steadily increase (as shown by the response surface) when the inflammatory burden increases, and regulatory processes are minimal. This type of response illustrates a threshold, or in this case a functional tipping point, beyond which injury from inflammation suppresses compensatory mechanisms.

The response surface is unique in that it incorporates multiple outcomes in the dimension of respiratory function, rather than in isolation. The requirement of oxygen provides the most immediate indicator of gas exchange failure, whereas how long the patient is ventilated reflects the duration of respiratory failure. With the combination of these two factors, Figure 4 illustrates a complex response of the immune dysregulation rather than the simple communication of respiratory failure, helping to highlight the biological relevance of cytokine profiling at the time of birth.

Besides functional association, cytokine profiles show predictive capability in respiratory morbidity typologies. The model in Figure 5 makes use of neonatal cytokine information and is presented in actual machine learning fashion, as opposed to a machine learning model schematic. The model outputs a decision boundary in a lower-dimensional space. From a receiver operating characteristic (ROC) perspective, the model demonstrates the ability to differentiate neonates who experience varying levels of respiratory morbidity. The border indicates that the inflammatory profiles captured at birth possess the discriminatory capacity to identify population-level respiratory phenotypes of high and low risk.



Figure 5. Predictive classification model for neonatal respiratory morbidity

The respiratory morbidity predictive modeling in Figure 5 is the most impressive considering the biological diversity that exists in the neonatal population. The heterogeneity of the population is compounded by the wide variety of neonatal clinical characteristics including gestational age, birth weight, and perinatal exposures during childbirth; each of which can introduce variability and effectively hide the significance of relationships with predictor variables. The constant ability to maintain discrimination with cytokine profiles that continued to show variability underscores the importance in having multivariate predictive models. Most importantly, as the model emphasizes the relationships across multiple cytokines rather than the dominant response of any one cytokine, it results in reduced model noise, which ultimately increases its predictive utility and widespread applicability.

Table 3 summarizes clinical respiratory outcomes classified by risk of inflammation. Neonates were classified into low, moderate, and high cytokine burden categories using composite inflammatory indices derived from normalized cytokine profiles. Table 3 illustrates that higher inflammatory burden levels correspond to higher levels of respiratory distress syndrome, bronchopulmonary dysplasia, and prolonged oxygen dependency. The statistical annotations suggest that the differences are statistically significant, underscoring the biological significance of the stratification.

Table 3. Clinical respiratory outcomes stratified by inflammatory risk

Outcome measure	Low inflammatory risk	Moderate inflammatory risk	High inflammatory risk	Adjusted significance
Neonates (n)	24	26	22	—
Respiratory distress syndrome (RDS), %	12.5	34.6	63.6	< 0.001
Mechanical ventilation required, %	8.3	26.9	54.5	0.002
Duration of ventilation (days, mean ± SD)	1.2 ± 0.8	3.4 ± 1.6	6.1 ± 2.4	< 0.001
Oxygen dependency >72 h, %	16.7	38.5	68.2	< 0.001
Bronchopulmonary dysplasia (BPD), %	4.2	11.5	27.3	0.004

The correspondence of Table 3 and Figures 4 and 5 demonstrates the consistency of multiple analyses. Neonates with high inflammatory burden not only remain in correlation surfaces associated with higher oxygen and higher ventilation, but are also classified by the predictive model as high risk. On the other hand, low burden neonates are grouped in surfaces associated with well preserved respiratory functions and low morbidity. This strong convergence shows that the inflammatory burden truly captures the meaningful extent of respiratory vulnerability and not incidental variation.

The functional perspective of the stratification in Table 3 represents the continuum of the severity of the dysregulation of the cytokines. Low-burden neonates show inflammation profiles that suggest the presence of the immune regulation and lung adaptation. In contrast, high-burden neonates show the profile of the persistent immune activation and poor resolution. Moderate-burden neonates show inflammation profiles that may suggest both immune and lung adaptation. They demonstrate the shifting balance of inflammation and adaptation,

occurring during the early respiratory transition. This continuum approach is in accordance with the response surface calibrated in a non-linear manner in Figure 4. This approach also maintains the complexity of the phenomena and the avoidance of a simplistic and binary division of the phenomenon into high and low risk.

The nature of the findings is predictive, enhancing early clinical decision-making. The capture of the cytokine profile of the newborn, in the hours following birth, is before the full expression of the respiratory morbidity. It, therefore, allows for a predictive stratification for the neonate. The study is not suggesting that we immediately apply the findings clinically; however, the findings show that the inflammatory profiles may assist in the expression of the risk factors already present and provide a biological understanding of the immune-mediated vulnerability. The inclusion of the cytokine risk components with clinical and gestational factors may assist in the prediction of the babies that will need monitoring and also those that will require additional respiratory support and monitoring.

Importantly, the predictive framework puts an emphasis on biological interpretability over algorithmic sophistication. The machine learning model presented in Figure 5 aims to tackle data on cytokines while keeping the obscurity of the mechanisms in the background. This model, and its description, may best fit the translational priorities in neonatal research. Because given the level of transparency and complexity, clinical practitioners are more likely to endorse it.

5. Conclusion

In this study, we have focused on the inflammatory cytokines present at birth which are meaningful signals of the newborn’s risk of developing respiratory complications. The early neonatal blood cytokines, which are present at birth, do not signify an immune system activation that is either temporary or nonspecific, but rather, the system's cytokines reflect a structured system's signal regarding the critical shift in the system's balance between the pro-inflammatory and the regulatory signals; this, during the transition to extrauterine life, is critical. The persistent correlation between the complexity of the cytokine response and the severity of the respiratory complication reinforces the immune condition at birth as a critical element of early pulmonary function determination, in addition to the traditionally defined criteria: gestational age and birth weight.

From a clinical standpoint, the findings justify the possible use of cytokine profiling for risk assessment and monitoring over time. Cytokine levels from birth or shortly thereafter indicate the eventual onset of respiratory complications, and therefore signal the neonates who may need extra monitoring and specialized respiratory support. A primary benefit of monitoring cytokines is that it reflects the immune system's behavior through multiple channels, as opposed to measuring single, isolated biomarkers. Thus, monitoring cytokines may add to the clinical diagnosis by providing a mechanism that explains the immune and respiratory system interactivity, which is typically overlooked by clinical assessments.

The findings also add to the understanding of the immune system's role in the programming of lung development. The link between early inflammatory dysregulation and adverse respiratory outcomes suggests that immune signals in the perinatal windows may influence the development of lungs and the subsequent susceptibility to respiratory complications. An excess of pro-inflammatory signals, without controlling inflammatory pathways, may trigger acute respiratory distress, but also undermine the development of the lungs, which emphasizes the early immune environment's long-term impact.

In summary, we propose an innovative approach for understanding and predicting the immune and respiratory morbidity in newborns, based on the profiling of inflammatory cytokines at birth. By connecting immune status and functional outcomes in the respiratory system, the crosstalk the immune and respiratory systems during adaptation underscores the importance and sets the stage for future research investigating the interactions of inflammatory pathways and the lung in order to promote better development in at risk neonates.

References

1. Jobe, Alan H., and Eduardo Bancalari. "An all-inclusive perspective on bronchopulmonary dysplasia." *The Journal of pediatrics* 234 (2021): 257-259.
2. Baker, Christopher D., and Steven H. Abman. "Impaired pulmonary vascular development in bronchopulmonary dysplasia." *Neonatology* 107.4 (2015): 344-351.
3. Whitsett, Jeffrey A., and Timothy E. Weaver. "Alveolar development and disease." *American journal of respiratory cell and molecular biology* 53.1 (2015): 1-7.
4. Wynn, James L., and Hector R. Wong. "Pathophysiology of neonatal sepsis." *Fetal and Neonatal Physiology* (2016): 1536.
5. Gilman-Sachs, Alice, et al. "Inflammation induced preterm labor and birth." *Journal of Reproductive Immunology* 129 (2018): 53-58.
6. World Health Organization. *WHO recommendations on antenatal corticosteroids for improving preterm birth outcomes*. World Health Organization, 2022.
7. Schmidt, Augusto F., et al. "Prenatal inflammation enhances antenatal corticosteroid–induced fetal lung maturation." *JCI insight* 5.24 (2020): e139452.
8. Jobe, Alan H. "Mechanisms of lung injury and bronchopulmonary dysplasia." *American journal of perinatology* 33.11 (2016): 1076-1078.
9. Miselli, Francesca, et al. "Escherichia coli is overtaking group B Streptococcus in early-onset neonatal sepsis." *Microorganisms* 10.10 (2022): 1878.
10. Yu, Xueyang, et al. "The cytokine TGF-β promotes the development and homeostasis of alveolar macrophages." *Immunity* 47.5 (2017): 903-912.
11. Thébaud, Bernard, et al. "Bronchopulmonary dysplasia." *Nature reviews Disease primers* 5.1 (2019): 78.
12. Hammoud, Majeda S., et al. "Cytokine profiles at birth and the risk of developing severe respiratory distress and chronic lung disease." *Journal of Research in Medical Sciences* 22.1 (2017): 62.
13. Sedney, Colleen J., and Eric T. Harvill. "The neonatal immune system and respiratory pathogens." *Microorganisms* 11.6 (2023): 1597.
14. Glaser, Kirsten, et al. "Perinatal Ureaplasma exposure is associated with increased risk of late onset sepsis and imbalanced inflammation in preterm infants and may add to lung injury." *Frontiers in Cellular and Infection Microbiology* 9 (2019): 68.
15. Leroy, Sandrine, et al. "A time-based analysis of inflammation in infants at risk of bronchopulmonary dysplasia." *the Journal of Pediatrics* 192 (2018): 60-65.
16. Keskinidou, Chrysi, et al. "Mechanistic understanding of lung inflammation: recent advances and emerging techniques." *Journal of inflammation research* (2022): 3501-3546.